Hyderabad: Dr Reddy’s Laboratories Ltd today launched Repatha™ (evolocumab) 140 mg/ml, the first and only PCSK9 Inhibitor* available in India, approved by the Drug Controller General India (DCGI).
M.V. Ramana, CEO, Branded Markets (India and Emerging Markets) said, “The launch of Repatha™ is another significant addition to Dr. Reddy’s Cardiovascular portfolio, which we believe will provide a unique treatment option to patients in India who are at risk of Heart Attack, Stroke and Coronary problems.” In India, Repatha™ is distributed by Dr. Reddy’s and manufactured by Amgen.
*PCSK9 Inhibitors are a new class of lipid lowering drugs. They target and inactivate a specific protein in the liver called proprotein convertase subtilisin kexin 9. This leads to dramatic reduction in the amount of harmful LDL cholesterol circulating in the bloodstream. (NSS)
